supp.fit
All study protocols

Baikal Skullcap: study protocols

12 study groups say how much Baikal Skullcap participants took a day. These are the doses the studies gave. They are not a recommendation.

Baikal Skullcap: what the research found →

Dose per serving from research

12 study groups in 5 studies say how much Baikal Skullcap participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 33% of 12 study groups.

Daily doseStudy groups
10 mg to 25 mg
2
25 mg to 50 mg
0
50 mg to 100 mg
0
100 mg to 250 mg
2
250 mg to 500 mg
2
500 mg to 1 g
4
1 g to 2.5 g
2

Commonly used together

3 of 12 study groups took Baikal Skullcap with something else, but nothing that 3 or more different studies gave.

12 study groups

Study
The Effects of Combined Scutellaria and Saffron Supplementation on Mood Regulation in Participants with Mild-to-Moderate Depressive Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study
2025 · SCUTELL’UP · Adults aged 18–75, women and men, with a recent depressive episode and mild-to-moderate depressive symptoms
20 mg6 weeks42
The Effects of Combined Scutellaria and Saffron Supplementation on Mood Regulation in Participants with Mild-to-Moderate Depressive Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study
2025 · SAFFR’UP · Adults aged 18–75, women and men, with a recent depressive episode and mild-to-moderate depressive symptoms
20 mg6 weeks48
Effects of Acacia catechu and Scutellaria baicalensis extract on cognitive function in a healthy adult population: a double-blind, randomized, placebo-controlled trial
2025 · test product (TP) · Healthy adults; mean age 43 ± 8 years; 26 males and 59 females
240 mg4 weeks—
Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: A randomised, double-blind, placebo-controlled, crossover trial
2025 · herbal supplement · Adults aged 18–75, male and female, otherwise healthy and self-reporting stress (PSS score ≥13)
800 mg15 days35
Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study
2021 · 400 mg baicalein group in food-effect study · Healthy Chinese subjects
400 mg1 day10
Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study
2021 · 200 mg baicalein group · Healthy Chinese subjects
200 mg1 day—
Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study
2021 · 400 mg baicalein group · Healthy Chinese subjects
400 mg1 day—
Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study
2021 · 600 mg baicalein group · Healthy Chinese subjects
600 mg1 day—
Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled, single-dose phase I study
2021 · 800 mg baicalein group · Healthy Chinese subjects
800 mg1 day—
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study
2021 · 200 mg dose group · Healthy Chinese adults aged 18–40 years
600 mg10 days10
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study
2021 · 400 mg dose group · Healthy Chinese adults aged 18–40 years
1.2 g10 days10
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study
2021 · 600 mg dose group · Healthy Chinese adults aged 18–40 years
1.8 g10 days10